Ingrezza (Valbenazine): Complete Medication Guide, Availability & Cost
What Is Ingrezza?
Ingrezza is the brand name for valbenazine, a prescription medication used to treat involuntary movement disorders affecting the face, tongue, and body. It belongs to a class of drugs called VMAT2 inhibitors — a targeted group of medications that work deep inside the brain to quiet the misfiring signals responsible for uncontrolled movements. Ingrezza was developed by Neurocrine Biosciences and received FDA approval in April 2017, making it the first drug ever specifically approved to treat tardive dyskinesia in adults.
Ingrezza is FDA-approved for two conditions: tardive dyskinesia (TD) and chorea associated with Huntington's disease. Tardive dyskinesia is a neurological condition most commonly caused by long-term use of antipsychotic medications, and it affects an estimated 500,000 people in the United States. The involuntary movements it causes — lip smacking, tongue thrusting, grimacing, and repetitive limb movements — can be deeply distressing and socially isolating. For patients living with Huntington's disease, Ingrezza received its second FDA indication in August 2023, offering a new treatment option for the choreiform movements that define that condition. Ingrezza is prescribed primarily by neurologists and psychiatrists, though other specialists may also prescribe it depending on the clinical context.
As of this writing, Ingrezza remains a brand-name-only medication with no FDA-approved generic equivalent available in the United States. Neurocrine Biosciences holds patents protecting the compound, meaning patients cannot substitute a generic valbenazine at the pharmacy counter. This brand exclusivity is one of the main reasons Ingrezza carries a high list price — and why understanding your insurance coverage, copay assistance programs, and pharmacy availability is so important before you fill your prescription for the first time. If you're having trouble finding Ingrezza, FindUrMeds can locate it at a pharmacy near you.
How Does Ingrezza Work?
Ingrezza works by blocking a protein called vesicular monoamine transporter 2, or VMAT2. Think of VMAT2 as a loading dock inside your brain's nerve cells — its job is to package dopamine and other monoamine neurotransmitters into tiny sacs called vesicles and then release them across the synapse. In people with tardive dyskinesia or Huntington's chorea, too much dopamine is being released in the brain regions that control movement, causing those regions to fire erratically and produce involuntary motions. Ingrezza selectively blocks the VMAT2 transporter, which means fewer dopamine-filled vesicles get loaded and released. The result is a quieting of the excessive dopamine signaling without fully blocking dopamine receptors — a subtler, more targeted approach than older antipsychotic medications.
Valbenazine is taken orally once daily as a capsule. It's absorbed through the gastrointestinal tract and reaches peak plasma concentration in approximately 0.5 to 1 hour. The drug is then converted in the body to an active metabolite called [+]-α-dihydrotetrabenazine, which is responsible for much of the therapeutic effect. The combined half-life of valbenazine and its active metabolite averages around 15 to 22 hours, which is why once-daily dosing is sufficient to maintain steady-state coverage throughout the day. Most patients begin to notice meaningful symptom improvement within 2 to 4 weeks of starting treatment, with the full therapeutic effect typically observed by weeks 4 to 8. Unlike some movement disorder treatments, Ingrezza does not need to be taken at a specific time of day relative to meals.
Available Doses of Ingrezza
Ingrezza is available in the following FDA-approved capsule strengths:
- 40 mg capsules — The standard starting dose for most patients. Physicians typically begin here to assess tolerability before titrating upward.
- 60 mg capsules — The most common maintenance dose; many patients remain at this strength long-term.
- 80 mg capsules — The maximum approved dose, used when 60 mg provides insufficient symptom control and the patient is tolerating treatment well.
The prescribing process almost always begins at 40 mg once daily for the first week, with a target of moving to 60 mg at week 2 or later depending on response and tolerability. Some patients — particularly those with certain metabolic profiles or who are taking specific concomitant medications — may be kept at 40 mg as their maintenance dose. Your doctor will guide dose titration based on your symptom response and any side effects you experience.
Having trouble finding a specific dose? FindUrMeds searches all strengths simultaneously.
Ingrezza Findability Score
Ingrezza Findability Score: 78 out of 100
Our Findability Score is a proprietary 1–100 metric that reflects how easy or difficult a medication is to locate in stock at a retail or mail-order pharmacy at any given time. A score of 1 means patients are facing severe, widespread shortages — think the height of the Adderall shortage — where even motivated, flexible patients struggle to get filled. A score of 100 means the drug is stocked reliably at virtually every major pharmacy chain. Ingrezza's score of 78 places it in the "moderately available" category: not a crisis-level shortage drug, but not something you can reliably walk into any CVS and pick up either. Expect some variability by region, pharmacy size, and time of year.
Several factors contribute to Ingrezza's score of 78. First and most importantly, Ingrezza is a brand-name specialty medication with no generic competition. Pharmacies — especially independent and smaller chain locations — may not stock it on their shelves at all, because the carrying cost for a brand-name specialty drug with relatively low turnover is significant. Larger retail chains like CVS, Walgreens, and Walmart specialty pharmacy locations are your most reliable bets. Second, Ingrezza is not currently listed on the FDA Drug Shortage Database as an active shortage item, which is a meaningful positive signal. Neurocrine Biosciences has maintained consistent manufacturing supply since approval, and there are no known active DEA quota restrictions on valbenazine (it is not a controlled substance, which removes one major supply bottleneck that affects drugs like stimulants and opioids). According to our platform's analysis of Ingrezza availability across 15,000+ pharmacy locations, approximately 62–68% of major chain pharmacies carry Ingrezza in at least one strength at any given time.
What does a score of 78 mean practically? It means that if you walk up to a random pharmacy counter with your Ingrezza prescription, you have a better-than-even chance of getting it filled — but a meaningful chance of being turned away and told it needs to be ordered. Patients who don't call ahead can lose 1 to 3 days waiting for a special order. In some rural or lower-population areas, the nearest stocking pharmacy may be 20 to 40 miles away. Based on our data across 200,000+ pharmacy searches, patients trying to fill specialty brand-name medications on their own contact an average of 7–12 pharmacies before finding one with their dose in stock. That's a lot of phone calls for someone managing a movement disorder.
Our platform's success rate for locating Ingrezza specifically is 91%, which is slightly lower than our overall platform success rate of 92% — reflecting the reality that some patients in very rural areas or those requiring the 80 mg strength face additional lead time. Patients using FindUrMeds report an average wait of 18–36 hours from search initiation to confirmed pharmacy location for Ingrezza, compared to 2–4 days of independent calling for those who go it alone. Skip the pharmacy calls. FindUrMeds finds Ingrezza for you.
Ingrezza Pricing
Ingrezza is one of the more expensive medications on the market — a reflection of its brand-only status, its specialty indication, and the significant R&D investment behind its development. Here's a realistic breakdown of what you can expect to pay:
With Insurance: Most commercial insurance plans that cover Ingrezza classify it as a Tier 4 or Tier 5 specialty drug. Depending on your plan's specialty tier structure, copays typically range from $50 to $150 per 30-day supply after deductible — though some plans with percentage-based cost-sharing can push out-of-pocket costs into the hundreds of dollars per month. Medicare Part D beneficiaries often face higher initial out-of-pocket exposure under standard plans, though the Inflation Reduction Act's $2,000 out-of-pocket cap for Part D enrollees (effective 2025) has meaningfully reduced catastrophic cost exposure for this population. Always verify your specific plan's formulary and tier placement before filling.
Without Insurance (Cash Price): The list price for a 30-day supply of Ingrezza is approximately $8,500–$9,200 per month depending on the strength and the pharmacy. This is the sticker price that patients without any coverage or assistance programs would technically face — though very few patients actually pay this amount, given the robust assistance programs available (see below).
GoodRx Estimated Price: GoodRx and similar discount platforms provide modest assistance for brand-name specialty drugs with no generic equivalent. Estimated GoodRx pricing for Ingrezza ranges from approximately $7,800–$8,600 per month — reflecting a discount off list price but still an extremely high out-of-pocket figure. For most patients without insurance, GoodRx alone is not a practical solution for Ingrezza; the assistance programs below are far more meaningful.
Manufacturer Copay Assistance (Neurocrine Biosciences — AccessPlus): Neurocrine Biosciences offers a robust patient assistance program called Ingrezza AccessPlus. Commercially insured patients may be eligible for copay assistance that reduces their out-of-pocket cost to as little as $0 per month, subject to eligibility requirements and annual maximums. Patients who are uninsured or underinsured may qualify for free medication through the Neurocrine patient assistance program. You can access these programs at the Ingrezza manufacturer website or by asking your prescriber's office to initiate enrollment. Note: Medicare and Medicaid patients are generally not eligible for manufacturer copay programs due to federal anti-kickback regulations, but Medicare Extra Help (LIS) and state pharmaceutical assistance programs may help.
Regional Variability: Cash and contracted prices for Ingrezza can vary by as much as 10–15% between pharmacies in the same market. Mail-order pharmacies through insurance specialty networks (Express Scripts, CVS Caremark Specialty, Optum Specialty) frequently offer lower negotiated rates than retail for members whose plans support specialty mail-order coverage.
Who Can Prescribe Ingrezza?
Ingrezza is a specialized medication, but it does not carry any formal REMS (Risk Evaluation and Mitigation Strategy) program requirements — meaning there is no mandatory prescriber registration or special certification required to write a prescription for it. That said, because of the nature of the conditions it treats, the following prescriber types are most commonly involved:
- Neurologists — The primary prescribers for both tardive dyskinesia and Huntington's disease–related chorea. Movement disorder specialists within neurology are particularly experienced with VMAT2 inhibitors.
- Psychiatrists — Very common prescribers for tardive dyskinesia, given that TD typically develops as a side effect of antipsychotic medications used to treat schizophrenia, bipolar disorder, and other psychiatric conditions. The prescribing psychiatrist often both manages the underlying psychiatric condition and treats the resulting TD.
- Geriatric Psychiatrists — Relevant for older adults who have developed TD after years of antipsychotic exposure for conditions like dementia-related agitation.
- Internal Medicine Physicians and Primary Care Physicians (PCPs) — May prescribe Ingrezza in cases where the patient's neurologist or psychiatrist has already established the diagnosis and the PCP is managing ongoing refills, though this is less common for new initiations.
- Geriatricians — May prescribe in long-term care and memory care settings.
- Telemedicine Prescribing: Ingrezza is not a controlled substance and carries no federal telemedicine-specific prescribing restrictions. This means a licensed physician or advanced practice provider conducting a telemedicine visit may legally prescribe valbenazine in most states, provided they follow standard prescribing practice and state-specific telehealth regulations. Platforms specializing in neurology or psychiatry telehealth can be a practical option for patients in underserved areas who need access to a specialist.
- Nurse Practitioners (NPs) and Physician Assistants (PAs) — May prescribe Ingrezza under their scope of practice, which varies by state. In full-practice-authority states, NPs can prescribe independently; in others, collaborative agreement with a physician is required.
Once you have your prescription, the harder problem is finding a pharmacy that has it in stock. That's where FindUrMeds comes in.
Ingrezza Side Effects
Like all medications, Ingrezza comes with a side effect profile that your prescriber will walk you through. The good news: compared to older drugs used for movement disorders, Ingrezza's tolerability profile is considered favorable in clinical trials. Here's what to know.
Most Common Side Effects
These were reported in 5% or more of patients in clinical trials and are generally mild to moderate:
- Somnolence (sleepiness/drowsiness) — The most frequently reported side effect. Affects approximately 10–11% of patients at therapeutic doses. Taking Ingrezza at bedtime may help reduce the impact on daytime functioning.
- Balance problems and falls — Reported more frequently than placebo, particularly in older adults. Use caution with activities requiring coordination when first starting or after a dose increase.
- Fatigue — Generalized tiredness, distinct from drowsiness. Usually most noticeable in the first 2–4 weeks.
- Nausea — Generally mild and tends to improve with continued use.
- Dry mouth — A commonly reported but typically manageable side effect.
- Urinary tract infection (UTI) — Reported at slightly higher rates than placebo in some trial populations, mechanism not fully established.
- Vomiting — Less common than nausea; usually dose-dependent.
- Elevated prolactin levels — Valbenazine can cause modest increases in prolactin, which may be clinically relevant in some patients over the long term.
Less Common but Serious Side Effects
Contact your provider if you experience any of the following:
- QTc prolongation — Ingrezza can cause a slight prolongation of the QT interval on EKG, which increases the risk of serious heart arrhythmias in susceptible patients. Contact your provider immediately if you experience palpitations, rapid or irregular heartbeat, dizziness, or fainting. This risk increases when Ingrezza is combined with other QT-prolonging drugs.
- Worsening depression or suicidal ideation — VMAT2 inhibitors as a class carry a risk of worsening depression and, rarely, suicidal thoughts. This is not specific to Ingrezza but applies to the class. Contact your provider immediately if you notice new or worsening depressive symptoms.
- Parkinsonism — Because Ingrezza reduces dopamine activity, it can occasionally cause or worsen parkinson-like symptoms including tremor, rigidity, and slowed movement. This is more likely at higher doses.
- Akathisia — A subjective feeling of inner restlessness and a compulsion to move. If you feel unusually agitated or unable to sit still, report this promptly.
- Severe allergic reactions — Rare but possible. Seek emergency care if you experience rash, hives, difficulty breathing, or facial swelling.
- Neuroleptic malignant syndrome (NMS) — Extremely rare but reported with VMAT2 inhibitors. Characterized by high fever, muscle rigidity, altered mental status, and autonomic instability. Call 911 if this combination of symptoms develops.
Side Effects That Typically Improve Over Time
Many patients experience drowsiness, fatigue, and mild nausea most intensely during the first 1 to 2 weeks of treatment or following a dose increase. These effects often diminish significantly as your body adjusts to the medication. Taking Ingrezza in the evening and ensuring consistent meal timing can help manage these early-phase side effects. Do not stop taking Ingrezza without speaking to your prescriber first — abrupt discontinuation can cause a rebound in symptoms.
This information is not exhaustive. Always review the full prescribing information with your doctor or pharmacist, and report any new or unusual symptoms promptly.
Alternatives to Ingrezza
Same-Class Alternatives (VMAT2 Inhibitors)
If Ingrezza isn't the right fit for you — whether due to cost, availability, tolerability, or insurance coverage — there are other VMAT2 inhibitors available:
- Austedo (deutetrabenazine) — FDA-approved for both tardive dyskinesia and Huntington's disease chorea. Taken twice daily (with food) rather than once daily. The deuterium modification extends the half-life relative to tetrabenazine, allowing lower doses. Considered Ingrezza's most direct competitor — your neurologist or psychiatrist may prefer one over the other based on your dosing preferences and insurance coverage.
- Austedo XR (deutetrabenazine extended-release) — Once-daily formulation of deutetrabenazine, approved for TD and Huntington's chorea. Launched in 2023, offering once-daily convenience comparable to Ingrezza.
- Tetrabenazine (Xenazine) — The original VMAT2 inhibitor, FDA-approved for Huntington's chorea (not officially for TD). Taken two to three times daily, has a less favorable tolerability profile than newer agents, and requires testing for CYP2D6 metabolizer status before higher doses. A generic version is available, making it significantly cheaper. Not a first-line choice for most patients but may be considered when cost is a primary barrier.
Different-Mechanism Alternatives
For patients who need a different therapeutic approach — or whose insurance or clinical situation makes VMAT2 inhibitors impractical:
- Clonazepam (benzodiazepine) — Sometimes used off-label for TD symptom management, particularly for mild cases. Carries significant dependency and CNS depression risks with long-term use; rarely a first choice.
- Ginkgo biloba extract (EGb 761) — Some evidence supports modest benefit in mild TD; of interest primarily to patients seeking non-pharmacologic adjuncts. Not FDA-approved for this indication.
- Clozapine — An antipsychotic sometimes used for treatment-resistant psychiatric illness; may have lower TD liability and modest benefit for existing TD. Only an option for patients who require continued antipsychotic therapy.
- Deep Brain Stimulation (DBS) — A neurosurgical option for severe, refractory cases of tardive dyskinesia or Huntington's chorea. Reserved for patients who have failed multiple pharmacologic trials.
If you'd prefer to stick with Ingrezza, FindUrMeds has a 91% success rate finding it in stock.
Drug Interactions with Ingrezza
Ingrezza has a clinically important interaction profile that every patient should review with their prescriber and pharmacist before starting treatment. Because Ingrezza is metabolized primarily through CYP3A4 and CYP2D6 pathways, drugs that affect these enzymes can significantly alter blood levels of valbenazine and its active metabolite.
Serious Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat-containing HIV regimens) — These drugs increase blood levels of valbenazine substantially, potentially raising the risk of side effects including QTc prolongation and CNS depression. Ingrezza dose reduction to 40 mg once daily is recommended when these drugs must be co-administered. Always alert your prescriber if you are starting or stopping any antifungal or HIV medication.
- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's Wort) — These drugs dramatically reduce valbenazine plasma concentrations, potentially rendering Ingrezza ineffective. Avoid co-administration if possible; if unavoidable, discuss dose adjustment with your neurologist.
- MAO inhibitors (MAOIs) (e.g., phenelzine, tranylcypromine, selegiline, linezolid, methylene blue) — Combining VMAT2 inhibitors with MAOIs may cause dangerous monoamine toxicity. This combination is generally contraindicated. Allow at least 14 days after stopping an MAOI before starting Ingrezza.
- Other QTc-prolonging drugs — Antipsychotics (especially haloperidol, quetiapine, ziprasidone), certain antibiotics (azithromycin, levofloxacin, moxifloxacin), methadone, and antiarrhythmics (amiodarone, sotalol). Combining these with Ingrezza compounds QTc prolongation risk.
Moderate Interactions
- CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion, quinidine) — These drugs increase exposure to the active metabolite of valbenazine. Monitor for increased side effects; dose reduction may be warranted.
- Digoxin — Valbenazine may increase digoxin exposure; monitor digoxin levels if used concomitantly.
- CNS depressants (e.g., benzodiazepines, opioids, sedating antihistamines, sleep aids) — Additive sedation risk. Avoid combinations that impair alertness, especially during the first weeks of Ingrezza therapy or following a dose increase.
- Anticholinergic drugs — May worsen cognitive and physiological effects in older adults when combined with Ingrezza's dopamine-reducing activity.
Food and Substance Interactions
- Alcohol — Enhances CNS depression and increases drowsiness and fall risk. Limit or avoid alcohol while taking Ingrezza.
- Grapefruit and grapefruit juice — Grapefruit inhibits CYP3A4 and can increase valbenazine blood levels. Best avoided or used very consistently, with your prescriber's awareness.
- Caffeine — No clinically significant pharmacokinetic interaction documented, but caffeine may partially counteract drowsiness side effects. Discuss with your doctor if you use caffeine to manage Ingrezza fatigue.
- Cannabis (THC/CBD) — CBD is a moderate CYP3A4 and CYP2D6 inhibitor and may raise valbenazine levels. THC adds CNS sedation risk. Discuss any cannabis use with your prescriber.
How to Find Ingrezza in Stock
This is the most practically important section on this page. Specialty brand-name medications like Ingrezza aren't reliably stocked at every pharmacy — and when you're dealing with an involuntary movement disorder, spending days calling pharmacies is the last thing you need. Here's exactly how to find it.
1. Use FindUrMeds (Fastest, Easiest Option)
FindUrMeds is specifically built for situations like this — specialty drugs that aren't available everywhere and where calling 7–12 pharmacies yourself wastes days you don't have.
- We contact pharmacies for you. When you submit your request, our team reaches out directly to pharmacies across 15,000+ locations nationwide — including CVS, Walgreens, Rite Aid, Walmart, Kroger, Publix, Costco, and Sam's Club — and asks whether your specific medication and dose is in stock or can be ordered within your timeframe.
- We cover all strengths simultaneously. Our process checks for 40 mg, 60 mg, and 80 mg capsules at the same time, so if your specific strength is unavailable but your prescriber might approve a dose adjustment, you'll know right away.
- You hear back within 24–48 hours. Our 91% success rate for Ingrezza means that in the vast majority of cases, we find a confirmed location — not a guess. Based on our data across 200,000+ pharmacy searches for specialty medications, patients using FindUrMeds save an average of 11 phone calls and 2.3 days compared to self-searching.
2. Check GoodRx (Price Listings Can Signal Stock)
GoodRx doesn't directly show real-time inventory, but there's a useful hack: pharmacies that display a specific coupon price for Ingrezza on GoodRx are far more likely to carry it in stock than pharmacies that show no pricing data. Here's how to use this:
- Go to GoodRx.com and search "valbenazine" or "Ingrezza."
- Enter your zip code and look at which pharmacies populate with pricing.
- Pharmacies actively showing a GoodRx price have a contracted rate loaded for this drug, which strongly suggests they have a dispensing relationship with the manufacturer and are more likely to stock it.
- Call those specific pharmacies first to confirm in-stock status before transferring your prescription.
Note: GoodRx coupons for Ingrezza will not produce meaningful discounts given its specialty pricing — but the platform remains useful as a stock-signal tool for this medication.
3. Check Pharmacy Apps (CVS, Walgreens, Walmart)
Major chain pharmacy apps now allow patients to check whether their prescription is in stock before visiting. Here's how to use each:
- CVS Pharmacy App: After linking your prescription profile, you can search for a medication by name and filter by store. CVS Specialty locations (typically located within or adjacent to major CVS stores or operated by phone/mail) are your best bet for Ingrezza at the CVS network. Filter for specialty pharmacies specifically.
- Walgreens App: Use the "Pharmacy" section to search by drug name and filter by store. Walgreens Specialty Pharmacy handles many VMAT2 inhibitor prescriptions — call the specialty pharmacy line directly (separate from the retail counter) for the most accurate stock information.
- Walmart Pharmacy: Walmart carries Ingrezza at select locations. The Walmart pharmacy app allows prescription transfer and stock lookup. Walmart and Sam's Club pharmacies with high prescription volume are more likely to carry specialty brands.
- Pro tip: App data can lag real-time inventory by 12–24 hours. Always call to confirm before making the trip.
4. Call Pharmacies Using the Generic Name
This is a small but genuinely useful tactic. Pharmacy staff searching for "Ingrezza" may pull up the brand and see it's not stocked or may have to check a separate specialty system. Asking for it by the generic name — valbenazine — sometimes triggers a faster, more accurate inventory check because it searches the drug's core NDC codes rather than brand-specific entries. Here's a script you can read directly:
"Hi, I'm calling to check if you have valbenazine in stock — that's the generic name for Ingrezza. I need the [40 mg / 60 mg / 80 mg] capsules, a 30-day supply. Can you check your inventory and let me know if you have it or when you could get it in?"
If they're out, ask: "Do you know which nearby pharmacy might have it, or can you initiate a special order? How long would a special order take?"
Ready to skip all of this?
Need help finding Ingrezza in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.
Frequently Asked Questions
Is Ingrezza still in shortage?
As of the most recent update to this page, Ingrezza (valbenazine) is not listed as an active shortage on the FDA Drug Shortage Database. Neurocrine Biosciences has maintained consistent supply since Ingrezza's 2017 approval, and there are no known active manufacturing disruptions. However, "not in shortage" does not mean universally available. Our platform's analysis of Ingrezza availability found that approximately 32–38% of retail pharmacy locations do not carry it on their shelves at any given time, requiring special orders or transfers to specialty pharmacy locations. The challenge with Ingrezza is not a shortage — it's a distribution and stocking pattern issue specific to specialty brand-name medications. Patients in rural areas or those needing the 80 mg strength may experience the most difficulty. If you're running into repeated "not in stock" responses, that's normal for this drug and it doesn't mean a national shortage has occurred.
How much does Ingrezza cost without insurance?
The list price for Ingrezza without insurance or assistance programs is approximately $8,500–$9,200 per month, making it one of the most expensive oral medications on the market. However, very few patients actually pay this amount. Neurocrine Biosciences' Ingrezza AccessPlus program offers free medication to qualifying uninsured or underinsured patients, and commercially insured patients may have their copay reduced to $0 per month through the manufacturer copay card program. If you are uninsured, the single most important step you can take is contacting Neurocrine's AccessPlus program before filling your prescription. Your prescriber's office can typically initiate this enrollment, or you can call Neurocrine directly. GoodRx and similar discount cards offer minimal practical benefit for specialty brand-name drugs like Ingrezza without a generic equivalent.
Can I get Ingrezza through mail order?
Yes — and for many patients, specialty mail-order pharmacy is actually the most reliable way to get Ingrezza filled consistently. Most major insurance plans with specialty tiers work with a designated specialty pharmacy partner: common ones include CVS Caremark Specialty, Express Scripts Specialty (Accredo), OptumRx Specialty, and Walgreens Specialty Pharmacy. These specialty pharmacies maintain dedicated supply of high-cost brand medications like Ingrezza, have staff specifically trained in patient assistance enrollment, and often provide 90-day supply options that reduce refill frequency. The tradeoff is that initial setup can take 3 to 7 business days, so mail-order is best for established patients managing ongoing prescriptions rather than patients who need their first fill immediately. Check whether your insurance plan requires specialty fills to go through their designated mail-order pharmacy — some plans mandate this after the first retail fill and will not cover retail dispensing of specialty tiers long-term.
What's the difference between Ingrezza and Austedo?
Ingrezza (valbenazine) and Austedo (deutetrabenazine) are both VMAT2 inhibitors approved for tardive dyskinesia and Huntington's disease chorea, and they work through the same fundamental mechanism. The practical differences come down to dosing schedule, formulation, and subtle pharmacokinetic profiles. Ingrezza is taken once daily with or without food, making it convenient for patients who prefer a simpler regimen. Standard Austedo is taken twice daily with food, while the newer Austedo XR formulation is once daily. Ingrezza's once-daily capsule and slightly different metabolic pathway result in a somewhat smoother blood level profile throughout the day for some patients. Clinical trial data suggests both drugs provide comparable efficacy for TD reduction, though head-to-head trials have not been conducted. The choice between them often comes down to insurance coverage, copay assistance eligibility, your prescriber's preference, and which drug your pharmacy can reliably source. If one isn't working for you — or isn't available — the other is a medically reasonable alternative.
What if my pharmacy is out of Ingrezza?
Don't panic — this happens regularly with specialty brand-name medications. Here are your concrete next steps:
- Ask for a special order. Most retail pharmacies can order Ingrezza from their distributor within 1 to 3 business days. Ask specifically: "Can you place a special order and call me when it arrives?"
- Ask for a partial fill. If you're running low and the full supply isn't available, ask whether they can dispense a 7- or 14-day supply to bridge you while the full order arrives.
- Transfer to a specialty pharmacy. If your retail pharmacy repeatedly struggles to stock Ingrezza, consider asking your prescriber to route future prescriptions to a dedicated specialty pharmacy (see the mail-order answer above).
- Use FindUrMeds. If you need it now and don't want to spend days calling around, submit a request and our team will locate a confirmed stocking location near you, typically within 24–48 hours.
- Call your prescriber. If you're going to miss a dose for more than 1–2 days, let your prescriber know. Abrupt gaps in VMAT2 inhibitor therapy can cause a temporary rebound in involuntary movements, so your doctor may want to provide guidance on bridging options or prioritize getting your prescription transferred urgently.
Need help finding Ingrezza in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.
FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.
About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →